CORDIS
EU research results

CORDIS

English EN

Anti-tick Vaccines to Prevent Tick-borne Diseases in Europe

Project information

Grant agreement ID: 602272

Status

Closed project

  • Start date

    1 December 2013

  • End date

    30 November 2018

Funded under:

FP7-HEALTH

  • Overall budget:

    € 3 823 805

  • EU contribution

    € 2 999 785

Coordinated by:

ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM

Netherlands

Objective

Background Ixodes ricinus transmits bacterial, protozoal and viral pathogens that cause Lyme borreliosis, babesiosis and tick-borne encephalitis respectively and exceedingly affect Central and Eastern Europe (CEE). During feeding, ticks introduce salivary proteins in the skin that interfere with host defense mechanisms. However, in animals repeated tick infestations as well as vaccination against selected tick proteins can lead to decreased pathogen transmission by inhibiting tick feeding - known as ‘tick immunity’ - or by neutralizing tick proteins that facilitate the transmission of tick-borne pathogens (TBPs). Also humans with hypersensitivity to tick-bites have a lower risk of contracting tick-borne diseases (TBDs). Therefore, anti-tick vaccines encompass an innovative strategy to prevent TBDs in humans, or animals and wildlife to indirectly reduce the risk of contracting TBDs for humans.

Overall Objective To identify and characterize tick proteins involved in ‘tick immunity’ and TBP transmission and to use this knowledge to develop anti-tick vaccines to prevent multiple human TBDs.

Methods Using state of the art proteomic and transcriptomic approaches we will identify and characterize novel tick salivary gland proteins, which will be subsequently assessed as anti-tick vaccines to protect against LB, babesiosis and TBE in animal models. In addition, through an integrated and multidisciplinary approach involving CEE public health institutes, health organizations and industrial companies we will examine how to develop anti-tick vaccines and implement these in public health systems.

Impact ANTIDotE will deliver 1) essential knowledge on the biological mechanisms involved in the pathogenesis of TBDs, 2) proof of concept of an anti-tick vaccine protecting against multiple human TBPs and 3) plans for exploitation and implementation of anti-tick vaccines, significantly contributing to downscaling the severe medical and economic burden that TBDs have on societies.
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM

Address

Meibergdreef 15
1105az Amsterdam

Netherlands

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 988 320

Administrative Contact

Frank Groen (Mr.)

Participants (7)

VIROLOGICKY USTAV SLOVENSKEJ AKADEMIE VIED

Slovakia

Biologicke centrum AV CR, v. v. i.

Czechia

EU Contribution

€ 565 900

FREIE UNIVERSITAET BERLIN

Germany

EU Contribution

€ 466 100

ASOCIACION CENTRO DE INVESTIGACION COOPERATIVA EN BIOCIENCIAS

Spain

EU Contribution

€ 373 400

GENXPRO GMBH

Germany

EU Contribution

€ 208 700

RIJKSINSTITUUT VOOR VOLKSGEZONDHEID EN MILIEU

Netherlands

EU Contribution

€ 141 445

BIOMEDICINSKE CENTRUM SLOVENSKEJ AKADEMIE VIED

Slovakia

EU Contribution

€ 255 920

Project information

Grant agreement ID: 602272

Status

Closed project

  • Start date

    1 December 2013

  • End date

    30 November 2018

Funded under:

FP7-HEALTH

  • Overall budget:

    € 3 823 805

  • EU contribution

    € 2 999 785

Coordinated by:

ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM

Netherlands